Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Pfizer, XTANDI
Pfizer reports positive data from prostate cancer combination therapy trial
Pfizer has announced data from the Phase III trial of TALZENNA plus XTANDI in patients with metastatic castration-resistant prostate cancer.
Pfizer’s TALZENNA® in Combination with XTANDI® Prolongs Overall Survival in Phase 3 TALAPRO-2 Trial
(NYSE: PFE) today announced positive topline results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of TALZENNA ® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor,
Pfizer Reports Positive Topline Data From Phase 3 TALAPRO-2 Study Of Talzenna Plus Xtandi
Thursday reported positive topline results from the Phase 3 TALAPRO-2 study of Talzenna in combination with Xtandi
Pfizer announces positive data from late-stage trial of prostate cancer combo treatment
Pfizer Inc. announced positive results Thursday from the final analysis of data from a late-stage trial of a combination treatment for patients with metastatic castration-resistant prostate cancer, or mCRPC.
FiercePharma
6d
Pfizer targets broad Talzenna approval in prostate cancer as trial meets patient survival goal
In prostate cancer, Pfizer’s Talzenna already holds the broadest FDA approval within the PARP inhibitor class. | In prostate ...
BioSpace
6d
Pfizer Phase III Prostate Cancer Win Builds Case for Broader Label for Talzenna-Xtandi Combo
The overall survival data from the late-stage trial will help Pfizer in its bid to expand the label for Talzenna and Xtandi, ...
7d
Pfizer's cancer drug combo improves overall survival in late-stage study
Pfizer said on Thursday a combination of its drugs, Talzenna and Xtandi, helped prolong the lives of patients with a type of ...
The Pharma Letter
6d
Pfizer’s Talzenna and Xtandi combo prolongs OS in mCRPC
US pharma giant Pfizer today released positive top line results from the final prespecified overall survival (OS) analysis of ...
Targeted Oncology
6d
Talazoparib/Enzalutamide Combo Offers Significant Survival Benefits in Prostate Cancer
According to findings from the TALAPRO-2 study, the combination led to significant and meaningful improvements in overall ...
devdiscourse
6d
Pfizer's Breakthrough Cancer Combo and Global Health Updates
Pfizer's drug combination improves survival in prostate cancer patients. Starboard Value pressures Pfizer over board conduct.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback